SCHEMBL2786928

SCHEMBL2786928

O=C(Nc1nc2cccc(NC3CCCCC3)n2n1)c1ccc(CN2CCC(O)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 15/20 0.56
▸ JAK1 P23458 13/20 0.56
▸ JAK3 P52333 3/20 0.46
▸ TYK2 P29597 2/20 0.45
▸ STK10 O94804 1/20 0.45
▸ ABL1 P00519 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CSF1R P07333 1/20 0.45
▸ FLT1 P17948 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ FLT4 P35916 1/20 0.45
▸ FLT3 P36888 1/20 0.45
▸ STAT1 P42224 1/20 0.45
▸ IRAK1 P51617 1/20 0.45
▸ MAPK10 P53779 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ MERTK Q12866 1/20 0.45
▸ AAK1 Q2M2I8 1/20 0.45
▸ Q6ZSR9 Q6ZSR9 1/20 0.45
▸ ADCK1 Q86TW2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2787512 0.94 JAK2 (0.58) JAK2JAK1JAK3TYK2STK10
SCHEMBL2789362 0.94 JAK2 (0.58) JAK2JAK1JAK3TYK2STK10
SCHEMBL2771078 0.90 JAK1 (0.57) JAK2JAK1JAK3TYK2
SCHEMBL2786688 0.90 JAK2 (0.50) JAK2JAK1JAK3TYK2STK10
SCHEMBL2790696 0.89 JAK2 (0.49) JAK2JAK1JAK3TYK2STK10
SCHEMBL2787254 0.87 JAK2 (0.51) JAK2JAK1JAK3TYK2
SCHEMBL2789812 0.84 JAK2 (0.45) JAK2JAK1
SCHEMBL2787694 0.83 JAK1 (0.53) JAK2JAK1
SCHEMBL2790848 0.83 JAK1 (0.49) JAK2JAK1JAK3
SCHEMBL2790846 0.83 JAK1 (0.57) JAK2JAK1JAK3TYK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US claimed
US-8263595-B2 Triazolopyridine compounds and their use as ask inhibitors MERCK SERONO SA (CH) 2012-09-11 — — US claimed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US claimed
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 — — EP claimed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO claimed
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US disclosed
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US disclosed
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US disclosed
US-8263595-B2 Triazolopyridine compounds and their use as ask inhibitors MERCK SERONO SA (CH) 2012-09-11 — — US disclosed
US-8263595-B2 Triazolopyridine compounds and their use as ask inhibitors MERCK SERONO SA (CH) 2012-09-11 — — US disclosed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US disclosed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US disclosed
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 — — EP disclosed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MAP3K5, MAPKAPK5, MAP3K9 JAK2 228/4885JAK1 229/4885JAK3 452/4885
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MAP3K5, MAPKAPK5, MAP3K9 JAK2 228/4885JAK1 229/4885JAK3 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback